Tenofovir alafenamide for hepatitis B: evolution or revolution?

Chronic hepatitis B infection remains a global health burden despite existence of an eff ective vaccine. Infection with chronic hepatitis B and its sequelae lead to almost 800 000 deaths annually. Over the past decades, treatment of chronic hepatitis B has evolved considerably. Treatment with tenofovir disoproxil fumarate achieves viral suppression in more than 90% of patients during continuous therapy and leads to reversal of liver cirrhosis. Unfortunately, since loss of hepatitis B surface antigen (HBsAg) is rarely achieved and might take up to 30 years, treatment with tenofovir disoproxil fumarate is indefinite. [...]

• View at Publisher
• View at Scopus